Author: admin

Animal Disinfectants Market Set to Soar: $5.31 Billion Worth Market by 2030 – Arizton

“Global Animal Disinfectants Market Research Report by Arizton”

According to Arizton’s latest research report, the global animal disinfectants market is growing at a CAGR of 6.22% during 2024-2030.

       

Looking for More Information? Click: https://www.focusreports.store/report/animal-disinfectants-market-focused-insights

 

Report Scope:       

Market Size (2030): $5.31 Billion 

Market Size (2024): $3.69 Billion 

CAGR (2024-2030): 6.22% 

Historic Year: 2021-2023 

Base Year: 2024 

Forecast Year: 2025-2030 

Market Segmentation: Product, Form, Application, Distribution Channel, and Geography

Geographical Analysis: North America, Europe, APAC, Latin America, and Middle East & Africa 

 

Market Overview

The global animal disinfectants market is experiencing significant growth, driven by technological advancements, the development of eco-friendly and biodegradable solutions, and increasing demand for poultry disinfectants, alongside factors like the growth of animal care centers, intensified animal farming, and rising infectious diseases. Consumer preferences are shifting towards sustainable options, and regular disinfection in poultry farming is essential to prevent disease transmission. Specialized disinfectants are in high demand from veterinary clinics, while general products are widely available in pharmacies and agricultural settings. Major market players include DeLaval Inc, Ecolab, and Zoetis, with ongoing innovations like electrostatic spraying and nanotechnology improving disinfectant efficacy. China dominates the APAC region, fueled by growing biosecurity awareness and its large livestock industry.

 

Expansion of Animal Care Centers Boosting Revenue in the Animal Disinfectants Market

The growth in animal care centers is a significant trend in the global animal disinfectants market, contributing to its increasing revenue. This expansion is driven by several factors, including the premiumization of animal care, the humanization of animals, heightened awareness of zoonotic diseases, growth in veterinary services, innovations in disinfectant care, and a greater focus on preventive health measures. Rising disposable incomes, lifestyle changes, and urbanization have led to a global increase in animal ownership, fueling demand for hygiene products such as animal disinfectants. As pet owners become more conscious of maintaining the health and hygiene of their animals, there is greater investment in disinfecting grooming spaces, veterinary clinics, and living areas. With growing concerns over zoonotic diseases, both professionals and pet owners are prioritizing disinfectants to reduce health risks.

 

Additionally, stringent regulations from industry bodies and governments regarding hygiene standards for animal care facilities have encouraged the use of high-quality disinfectants. In the U.S., the number of animal shelters is increasing, with around 3,500 shelters and 6.3 million animals entering them annually, according to the American Society for the Prevention of Cruelty to Animals (ASPCA). The rise of veterinary hospitals and clinics has further increased the use of disinfectants to maintain sterile environments. Overall, the regular use of animal disinfectants is becoming an essential component of preventive healthcare for animals, driving market growth and boosting revenue by minimizing the risks of diseases and infections.

 

Recent Vendor Activities

  • In 2024, the leading animal disinfectant company, DeLaval Inc. launched its product Titan. It is a pioneering barrier teat disinfectant for automated spray systems. It’s one of the best developments for the dairy application and one of the first of its kind on the market. Titan represents a significant advancement in udder health management. Its innovative film-forming technology creates a barrier film on the teats, helping to protect against environmental pathogens like S. uberis and E. coli – prevalent causes of mastitis.
  • In 2024, a food and animal safety solution company, Neogen Corporation launched Farm Fluid MAX disinfectant in the UK poultry and livestock market. In the coming years, it will be available in other European markets. This dual-action disinfectant is designed for challenging farm conditions and is formulated for use as part of a Neogen Pathogen Program.

 

The Role of Offline Sales Channels in the Animal Disinfectants Market

The offline segment of the animal disinfectants market includes direct sales by manufacturers, retail stores, agricultural supply stores, veterinary pharmacies, and more. Veterinary clinics and hospitals often play a significant role by recommending and selling disinfectants directly to animal owners, offering expert guidance on product usage and specifications. Many pet owners trust their vets’ advice when selecting disinfectants. Livestock producers and farmers typically purchase disinfectants in bulk from agricultural supply stores, benefiting from discounted prices on large quantities and strong relationships built between vendors and buyers. Drugstores and pharmacies, though convenient for smaller needs, contribute less to the market due to their limited selection of specialized disinfectants. While the demand for specialized disinfectants continues to rise in veterinary clinics, general animal disinfectants are more readily available in pharmacies and agricultural outlets. Although online sales channels are expanding, offline stores will continue to be crucial in the animal disinfectants market, especially for personalized advice and bulk purchases.

 

China’s Dominance in the APAC Animal Disinfectants Market

China holds a dominant market share in the APAC animal disinfectants market, driven by factors such as increased awareness of biosecurity and animal health, along with its massive livestock industry. As the world’s largest producer of poultry, eggs, and pork, China has a significant demand for animal disinfectants to prevent disease spread and manage outbreaks. In 2020, China had over 5.7 billion poultry, and by 2021, its population consumed around 57 million tons of pork, creating a substantial need for disinfectants to support intensive farming operations. Disease outbreaks, like Avian Influenza and African Swine Fever (ASF), have highlighted the importance of effective disinfection practices. The Chinese government is committed to animal health and food safety, implementing strict regulations regarding animal disinfectants in livestock production. The market is competitive, with both global and domestic disinfectant brands available, offering products such as iodophors, aldehydes, phenols, and quaternary ammonium compounds. Additionally, there is growing demand for sustainable and biodegradable disinfectant options, which is expected to drive further market growth in China during the forecast period.

 

Looking for More Information? Click: https://www.focusreports.store/report/animal-disinfectants-market-focused-insights

 

Segmentation & Forecasts

 

Product

  • Iodine
  • Lactic Acid
  • Hydrogen Peroxide
  • Others

 

Form

  • Liquid
  • Powder
  • Others

 

Application

  • Dairy & Ruminants
  • Poultry
  • Swine
  • Aquaculture
  • Equine

 

Distribution Channel

  • Offline
  • Online

 

Geography

 

North America

  • The US
  • Canada

 

Europe

  • Germany
  • France
  • The UK
  • Italy
  • Spain

 

APAC

  • China
  • Japan
  • South Korea
  • Australia
  • India

 

Latin America

  • Brazil
  • Mexico

 

Middle East & Africa

  • Turkey
  • South Africa
  • Saudi Arabia

 

Vendor Lists

  • DeLaval Inc
  • Ecolab
  • Evans Vanodine International PLC
  • Evonik Industries AG
  • GEA Group
  • KERSIA GROUP
  • LANXESS
  • Neogen Corporation
  • Solvay
  • Zoetis Services LLC
  • AdvaCare Pharma
  • Albert Kerbl GmbH
  • Bona AB
  • Elanco Animal Health Incorporated
  • FINK TEC GmbH
  • G Shepherd Animal Health
  • Kemin Industries, Inc.
  • Laboratoires CEETAL
  • PCC Group
  • Planet Pets
  • Sanosil AG
  • Solenis International LLC
  • Stepan Company
  • Steroplast Healthcare Limited
  • STOCKMEIER Group
  • Sunways Bioscience LLP
  • Thymox
  • Veesure
  • Vetoquinol
  • Virbac
  • Virox

      

What Key Findings Will Our Research Analysis Reveal?     

How big is the global animal disinfectants market?

Which region holds the largest share of the global animal disinfectants market?

Who are the major players in the global animal disinfectants market?

         

Why Arizton?                                                

100% Customer Satisfaction                                                

24×7 availability – we are always there when you need us                                                

200+ Fortune 500 Companies trust Arizton’s report                                                

80% of our reports are exclusive and first in the industry                                                

100% more data and analysis                                                

1500+ reports published till date                              

                   

Post-Purchase Benefit                                            

  • 1hr of free analyst discussion                                            
  • 10% off on customization                         

                  

About Us:                                                                                     

Arizton Advisory and Intelligence is an innovative and quality-driven firm that offers cutting-edge research solutions to clients worldwide. We excel in providing comprehensive market intelligence reports and advisory and consulting services.

We offer comprehensive market research reports on consumer goods & retail technology, automotive and mobility, smart tech, healthcare, life sciences, industrial machinery, chemicals, materials, I.T. and media, logistics, and packaging. These reports contain detailed industry analysis, market size, share, growth drivers, and trend forecasts. 

Arizton comprises a team of exuberant and well-experienced analysts who have mastered generating incisive reports. Our specialist analysts possess exemplary skills in market research. We train our team in advanced research practices, techniques, and ethics to outperform in fabricating impregnable research reports.    

Media Contact
Company Name: Arizton Advisory & Intelligence
Contact Person: Jessica
Email: Send Email
Phone: +1 3122332770
Country: United States
Website: https://www.focusreports.store/report/animal-disinfectants-market-focused-insights

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Animal Disinfectants Market Set to Soar: $5.31 Billion Worth Market by 2030 – Arizton

Coronary Artery Disease Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies

DelveInsight’s, “Coronary Artery Disease Pipeline Insight” report provides comprehensive insights about 30+ companies and 25+ pipeline drugs in Coronary Artery Disease pipeline landscape. It covers the Coronary Artery Disease pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Coronary Artery Disease therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Stay ahead with the latest insights! Download DelveInsight’s comprehensive Coronary Artery Disease Pipeline Report to explore emerging therapies, key Coronary Artery Disease Companies, and future Coronary Artery Disease treatment landscapes @ Coronary Artery Disease Pipeline Outlook Report

Key Takeaways from the Coronary Artery Disease Pipeline Report

  • In February 2025:- MedTrace Pharma A/S:- This a Phase 3, prospective, open-label, multicenter study of [15-O]-H2O injection for PET imaging of subjects with suspected CAD. Approximately 182 evaluable participants with suspected CAD referred for testing will be included in the study at approximately 10 study sites in the United States and Europe. Approximately 215 participants will be enrolled to account for an estimated 15% drop-out rate.
  • In February 2025:- Novartis Pharmaceuticals:- The purpose of this study is to evaluate the efficacy of inclisiran compared to placebo on top of maximally tolerated dose of statin therapy in reducing total coronary atheroma volume assessed by CCTA in participants with a diagnosis of Non-Obstructive Coronary Artery Disease (NOCAD) without previous cardiovascular events, who have an LDL-C ≥55 mg/dL (1.4 mmol//L), no significant pressure drop in Fractional Flow Reserve Computed Tomography (FFRCT) and a CT-adapted Leaman score >5 despite the use of maximally tolerated statin therapy(and if applicable, another LLT on top of statin therapy for at least 30 days in up to 20% of randomized participants).
  • In February 2025:- Beijing Inno Medicine Co., Ltd.:- This study is to evaluate the efficacy and safety of intravenously administered YN001 in patients with coronary atherosclerosis in Australia. This study will be conducted in eligible participants with a diagnosis of coronary atherosclerosis, and at least 1 coronary artery is blocked determined by coronary computed tomography angiography (CCTA)
  • DelveInsight’s Coronary Artery Disease pipeline report depicts a robust space with 30+ active players working to develop 25+ pipeline therapies for Coronary Artery Disease treatment.
  • The leading Coronary Artery Disease Companies such as Novartis Pharmaceuticals, Amgen, Imbria Pharmaceuticals, Inc., AstraZeneca, Jiangsu Vcare Pharmatech, GE Healthcare, and others.
  • Promising Coronary Artery Disease Therapies such as Rosuvastatin, Atorvastatin, Hexadecasaccharide (SR123781A), Rosuvastatin, Rimonabant (SR141716), Rosuvastatin calcium, and others.

Discover how the Coronary Artery Disease treatment paradigm is evolving. Access DelveInsight’s in-depth Coronary Artery Disease Pipeline Analysis for a closer look at promising breakthroughs @ Coronary Artery Disease Clinical Trials and Studies

Coronary Artery Disease Emerging Drugs

  • Flurpiridaz F-18: GE Healthcare

Flurpiridaz F-18, a fluorine 18-labeled agent was developed by Lantheus Medical Imaging for the diagnosis of coronary artery disease (CAD), the most common form of heart disease. Flurpiridaz F 18 is an investigational positron emission tomography (PET) myocardial perfusion imaging (MPI) agent. GE Healthcare has launched a second Phase III clinical trial for the use of Flurpiridaz 18F Injection in PET myocardial perfusion imaging (MPI) to detect CAD. Currently, it is in Phase III stage of clinical trial evaluation to treat Coronary Artery Disease.

  • Evolocumab: Amgen

Evolocumab injection is used to reduce the risk of a stroke or heart attack or the need for coronary artery bypass (CABG) surgery in people with cardiovascular disease. Evolocumab injection is also used along with diet alone or in combination with other cholesterol-lowering medications such as HMG-CoA reductase inhibitors (statins) or ezetimbe (Zetia) to decrease the amount of low-density lipoprotein (LDL) cholesterol (‘bad cholesterol’) in the blood, including people who have familial heterozygous hypercholesterolemia. It is also used along with diet changes and other treatments to reduce the amount low-density lipoprotein (LDL) cholesterol in the blood in people that have homozygous familial hypercholesterolemia. It is in a class of medications called proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitor monoclonal antibody. It works by blocking the production of LDL cholesterol in the body to decrease the amount of cholesterol that may build up on the walls of the arteries and block blood flow to the heart, brain, and other parts of the body. Currently, it is in Phase III stage of clinical trial evaluation to treat Coronary Artery Disease.

  • Revacept: advanceCor

Revacept seals the lesion in a blood vessel like a plaster. It acts locally at the ruptured plaque instead of involving the complete organism, as is the case for all established drugs. Revacept has proven to be very effective in laboratory tests with platelets and in animal experiments. In a Phase I clinical trial with volunteers, it was shown to be very well tolerated at all dosages. It induced a specific and dose-dependent inhibition of aggregation (clumping of platelets) in the blood of the volunteers without any relevant side effects. In particular, general haemostasis was not affected: The bleeding time was not prolonged by Revacept and there were no bleeding complications and no reduction in platelet count (thrombopenia). Currently, it is in Phase II stage of clinical trial evaluation to treat Coronary Artery Disease.

The Coronary Artery Disease pipeline report provides insights into

  • The report provides detailed insights about companies that are developing therapies for the treatment of Coronary Artery Disease with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Coronary Artery Disease Treatment.
  • Coronary Artery Disease Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Coronary Artery Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Coronary Artery Disease market.

Get a detailed analysis of the latest innovations in the Coronary Artery Disease pipeline. Explore DelveInsight’s expert-driven report today! @ Coronary Artery Disease Unmet Needs

Coronary Artery Disease Companies

Novartis Pharmaceuticals, Amgen, Imbria Pharmaceuticals, Inc., AstraZeneca, Jiangsu Vcare Pharmatech, GE Healthcare, and others.

Coronary Artery Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

  • Oral
  • Parenteral
  • Intravenous
  • Subcutaneous
  • Topical

Coronary Artery Disease Products have been categorized under various Molecule types such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy

Download DelveInsight’s latest report to gain strategic insights into upcoming Coronary Artery Disease Therapies and key Coronary Artery Disease Developments @ Coronary Artery Disease Market Drivers and Barriers, and Future Perspectives

Scope of the Coronary Artery Disease Pipeline Report

  • Coverage- Global
  • Coronary Artery Disease Companies- Novartis Pharmaceuticals, Amgen, Imbria Pharmaceuticals, Inc., AstraZeneca, Jiangsu Vcare Pharmatech, GE Healthcare, and others.
  • Coronary Artery Disease Therapies- Rosuvastatin, Atorvastatin, Hexadecasaccharide (SR123781A), Rosuvastatin, Rimonabant (SR141716), Rosuvastatin calcium, and others.
  • Coronary Artery Disease Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Coronary Artery Disease Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Which companies are leading the race in Coronary Artery Disease drug development? Find out in DelveInsight’s exclusive Coronary Artery Disease Pipeline Report—access it now! @ Coronary Artery Disease Emerging Drugs and Major Companies

Table of Content

  1. Introduction
  2. Executive Summary
  3. Coronary Artery Disease: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Coronary Artery Disease – DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Evolocumab: Amgen
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. Ninerafaxstat: Imbria Pharmaceuticals, Inc.
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. Drug profiles in the detailed report…..
  15. Inactive Products
  16. Coronary Artery Disease Key Companies
  17. Coronary Artery Disease Key Products
  18. Coronary Artery Disease- Unmet Needs
  19. Coronary Artery Disease- Market Drivers and Barriers
  20. Coronary Artery Disease- Future Perspectives and Conclusion
  21. Coronary Artery Disease Analyst Views
  22. Coronary Artery Disease Key Companies
  23. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/functional-dyspepsia-pipeline-insight

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Coronary Artery Disease Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies

Bio-based Leather Market Size, Growth Rate, Industry opportunities with Top Key Players and Expert Review by 2028

“Browse 250 market data Tables and 40 Figures spread through 236 Pages and in-depth TOC on “Bio-based Leather Market””
The bio-based leather market is gaining traction as sustainability drives demand for eco-friendly alternatives to traditional leather. Innovations in plant-based and lab-grown materials are fueling growth, with the fashion and automotive industries leading adoption. As regulations tighten, bio-based leather is set to expand, offering a greener future.

In terms of value, the bio-based leather market is estimated to grow from USD 107 million in 2023 to USD 216 million by 2028, at a CAGR of 15.0%. The market research report is a comprehensive analysis of the bio-based leather market trends, future prospects, and other pivotal factors that drive the market. Rising demand for eco-friendly and sustainable leather materials from industries such as footwear, garments & accessories, furniture, and automotive for a variety of applications is leading the market. In addition, most of the key industry players are investing in heavy research and development for more durable materials. During the forecast period, this is anticipated to expand the bio-based leather market even more. In contrast, the market growth is being constrained by expensive product costs & R&D expenses and the durability of bio-based leather.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=206086810

“Mushroom was the largest source for bio-based leather market in 2022 in terms of value.”

The bio-based leather market is experiencing significant growth driven by several key factors. Mushrooms, specifically mycelium, have attracted attention as a prospective source in the bio-based leather market for various reasons. Mycelium leather can be manufactured to have specific features such as texture, thickness, and durability, making it versatile and appropriate for a wide range of applications such as fashion, accessories, and furniture. Biotechnology and material science advancements have improved the manufacturing method and quality of mushroom-based leather, making it a more viable choice for the fashion and textile industries.

“Garments & accessories segment is estimated to be the largest end-use industry in bio-based leather market between 2023 and 2028 in terms of value.”

The bio-based leather market has been gradually expanding, with increased investment and research in producing better materials and manufacturing methods. Clothing and accessories, such as shoes, handbags, belts, and wallets, are high-fashion consumer items. People seek apparel and accessories that are not only functional but also fashionable and trendy. Bio-based leather is a sustainable and ethical solution that meets the growing demand for cruelty-free and eco-friendly design. The texture, appearance, and feel of bio-based leather can be created to closely resemble that of animal leather. This makes it a popular alternative for fashion designers and brands looking to build items that meet consumers’ quality and aesthetic requirements.

“Europe was the largest region for the bio-basd leather market in 2022, in terms of value.”

The expansion of the bio-based leather market in the Europe region is primarily due to strict regulations regarding animal leather and the product sustainability. The Europe area has a sizable consumer market, making it an appealing destination for bio-based leather manufacturers and investors. On the other hand, Asia Pacific is estimated to be the fastest growing region in this market. Many Asia Pacific countries, particularly China and India, have expressed a desire to promote green and sustainable industries. Notably, most of this growth in the Asia Pacific region is anticipated to be concentrated in key countries such as India, China, South Korea, Japan, and various Southeast Asian nations.

Get a Sample Copy of This Report: https://www.marketsandmarkets.com/requestsampleNew.asp?id=206086810

Bio-Based Leather Companies

The key players in this market are Natural Fiber Welding, Inc. (US), Ananas Anam Ltd. (UK), MycoWorks Inc. (US), Bolt Threads Inc. (US), Modern Meadows (US), Adriano di Marti (Mexico), Ultrafabrics Holdings Co., Ltd. (US), Beyond Leather Materials (Denmark), Fruitleather Rotterdam (Netherlands), and VEGEA (Italy). These companies are known for developing a wide variety of bio-based leather used in various end-use industries. To address the rising demand for bio-based leather across a range of applications, players in the bio-based leather market are primarily focusing on their research and development. Companies may improve their source range and better quality of leather to promote bio-based leather.

The new product launches between 2019 and 2023 have had a substantial influence on the expansion of the bio-based leather market. Different businesses have used various approaches to strengthen their positions in the bio-based leather market. For instance, Natural Fiber Welding, Inc., MycoWorks Inc., Bolt Threads Inc., Modern Meadows, Adriano di Marti, and Ultrafabrics Holdings Co., Ltd. primarily focus on the North American and South American regions, whereas Ananas Anam Ltd., Beyond Leather Materials, Fruitleather Rotterdam, and VEGEA has a major concentration on the European region. In essence, these businesses have solidified their presence in their home regions and are looking for ways to diversify geographically to grow their company operations. Additionally, during the past few years, all these companies have been committed to strengthening their product portfolios and market presence through strategic alliances.

Natural Fiber Welding, Inc. is a precursor in the field of biotechnology in the US. Natural Fiber Welding, Inc. has emerged as a pioneer in the development of sustainable materials. The core focus of the company is the research and commercialization of new, plant-based materials that are environmentally friendly, adaptable and have the potential to replace traditional materials in a variety of industries. Natural Fiber Welding, Inc.’s innovative method, “Mirum,” transforms natural fibers and agricultural leftovers into strong, durable, and customizable materials. For instance, in June 2023, the company announced a partnership with Ahima that will make it easier to develop footwear made with MIRUM. This partnership will help the company to cover a wide range of markets. Moreover, in February 2023, the company announced the partnership with Lenzing AG to offer TENCEL branded fibers as another backer option for Natural Fiber Welding, Inc. patented plant-based technology, MIRUM. The partnership will help the company to develop infinite possibilities for application from the new material.

Inquire Before Buying: https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=206086810

Ananas Anam Ltd. is a pioneering sustainable materials company known for its innovative creation, Pinatex. The company has revolutionized the fashion and textile industries with its plant-based, non-woven textile material made from pineapple leaf fibers. Pinatex is derived from the byproduct of pineapple cultivation, reducing agricultural waste. Ananas Anam Ltd. has garnered global recognition for its commitment to sustainability and ethical practices. The company collaborates with renowned brands and designers to incorporate Pinatex into their products, offering a cruelty-free and sustainable alternative to traditional leather and synthetic materials. For instance, in July 2021, the company entered a partnership with Dole Sunshine Company to access a larger volume of pineapple fibers to meet the increasing demand for Pinatex.

About MarketsandMarkets™

MarketsandMarkets™ has been recognized as one of America’s best management consulting firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.

Earlier this year, we made a formal transformation into one of America’s best management consulting firms as per a survey conducted by Forbes.

The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the ‘GIVE Growth’ principle, we work with several Forbes Global 2000 B2B companies – helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email: Send Email
Phone: 18886006441
Address:1615 South Congress Ave. Suite 103, Delray Beach, FL 33445
City: Florida
State: Florida
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/bio-based-leather-market-206086810.html

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Bio-based Leather Market Size, Growth Rate, Industry opportunities with Top Key Players and Expert Review by 2028

Queens Pedestrian Accident Lawyer Keetick L. Sanchez Highlights Legal Options for Injured Pedestrians

Queens pedestrian accident lawyer Keetick L. Sanchez (https://accidentlawyer-queens.com/queens-pedestrian-accident-lawyer/), of K L Sanchez Law Office, P.C., provides crucial legal guidance to individuals injured in pedestrian accidents, helping them manage the complex aspects of insurance claims and lawsuits. With the busy streets of Queens posing constant risks, victims often face serious injuries and financial uncertainty. Securing fair compensation can be challenging, as insurance companies frequently offer settlements that do not fully cover medical expenses, lost wages, and long-term recovery costs. Having legal representation can help injured pedestrians understand their rights and pursue the compensation they deserve.

Given the complexity of pedestrian accident cases, Queens pedestrian accident lawyer Keetick L. Sanchez emphasizes the importance of acting quickly. “Pedestrian accidents can lead to life-changing injuries, and victims need to be aware of their legal rights. Seeking legal assistance early helps ensure that critical evidence is preserved and that victims have the best chance at securing the compensation they need for their recovery,” says Sanchez.

Pedestrian accidents in Queens are often caused by factors such as distracted driving, speeding, and failure to yield at crosswalks. High-risk areas such as Queens Boulevard, also known as the “Boulevard of Death,” and Roosevelt Avenue, where foot traffic is heavy, see frequent pedestrian-related incidents. The Queens pedestrian accident lawyer also notes that poor visibility, left-turn collisions, and reckless driving further contribute to these accidents, increasing the likelihood of severe injuries.

A Queens pedestrian accident lawyer can help identify the cause of an accident and determine liability. Many accidents occur because drivers fail to follow traffic laws, but in some cases, pedestrians may also bear partial responsibility. New York’s comparative negligence rule allows victims to recover damages even if they were partially at fault, but their compensation is reduced by their percentage of responsibility.

Pedestrians injured in accidents may suffer from traumatic brain injuries, spinal cord damage, broken bones, and internal injuries. These injuries often require extensive medical treatment and long-term rehabilitation, adding to the financial burden of the victim and their family.

New York’s no-fault insurance system covers medical expenses and lost wages up to $50,000, but it does not compensate for pain and suffering. Victims who suffer serious injuries may file a lawsuit to seek additional damages. Keetick L. Sanchez stresses the importance of understanding these options, stating, “New York’s no-fault system provides initial relief, but for those with serious injuries, pursuing additional compensation through legal action may be necessary to cover long-term expenses and non-economic losses.”

A Queens pedestrian accident lawyer can also help victims explore other sources of compensation, such as the at-fault driver’s insurance, personal health insurance, and personal injury lawsuits. Cases involving hit-and-run accidents or uninsured drivers require a different legal approach, making experienced legal representation crucial.

Pedestrian accident victims in New York must adhere to strict filing deadlines to seek compensation. The statute of limitations for personal injury claims is generally three years from the date of the accident, while wrongful death claims must be filed within two years of the victim’s passing. Cases involving government entities, such as those caused by poorly maintained roads or malfunctioning traffic signals, require a notice of claim to be filed within 90 days of the incident.

Delaying legal action can weaken a case, as crucial evidence such as surveillance footage and witness testimony may become unavailable over time. Keetick L. Sanchez advises victims to seek legal counsel as soon as possible, helping ensure they meet all necessary deadlines and have a strong case.

Establishing liability in pedestrian accident cases is critical to securing compensation. While drivers are often at fault, pedestrians who fail to follow traffic laws or act recklessly may share some responsibility. Additionally, third-party liability may come into play in cases involving employers, vehicle owners, or government agencies responsible for hazardous road conditions.

Pedestrian accidents can lead to life-altering consequences, and the recovery process can be overwhelming. Keetick L. Sanchez and the team at K L Sanchez Law Office, P.C. are dedicated to protecting the rights of injured pedestrians by handling the legal process while victims focus on healing.

Taking legal action promptly allows victims to pursue the financial support they need to rebuild their lives. Keetick L. Sanchez urges accident victims to seek legal counsel immediately to explore their options and move forward with confidence.

About K L Sanchez Law Office, P.C.:

K L Sanchez Law Office, P.C. is a Queens-based law firm dedicated to representing victims of personal injury accidents, including pedestrian accidents, construction accidents, and motor vehicle collisions. Led by Keetick L. Sanchez, the firm is committed to fighting for the rights of injured individuals, helping ensure they receive fair compensation for their losses.

Embeds:

Youtube Video: https://www.youtube.com/watch?v=RrTgja3zqgM

GMB: https://www.google.com/maps?cid=2729652254808699760

Email and website

Email: accidentlawny1@gmail.com

Website: https://accidentlawyer-queens.com/

Media Contact
Company Name: K L Sanchez Law Office, P.C.
Contact Person: Keetick Sanchez
Email: Send Email
Phone: (646) 701-7990
Address:3763 83rd St #1m
City: Jackson Heights
State: New York 11372
Country: United States
Website: https://accidentlawyer-queens.com

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Queens Pedestrian Accident Lawyer Keetick L. Sanchez Highlights Legal Options for Injured Pedestrians

SLKOR Semiconductor Launches New Products: RS485 Chips, CAN Chips, and Half-Bridge Drivers

SLKOR Semiconductor boasts a team of technical experts from Yonsei University in South Korea and Tsinghua University in China. As a national high-tech enterprise, the company mastered internationally advanced silicon carbide MOSFET production technology early in its establishment. Under the leadership of Mr. Song Shiqiang, SLKOR has evolved into an international company specializing in IP design, integrated circuit manufacturing, and associated sales and technical services, with over 20,000 global customers. Today, the “SLKOR” and “Kinghelm” brands are widely recognized and trusted by customers.

SLKOR places great emphasis on quality management, rigorously controlling every stage from product design to production and testing. The company holds ISO9001 quality management certification, as well as EU RoHS, REACH, and California Proposition 65 certifications. SLKOR has R&D facilities in Busan, South Korea, Beijing, and Suzhou, and maintains a laboratory and central warehouse at its headquarters in Shenzhen. The company’s product portfolio includes TVS diodes, power devices, and power management chips. Recently, SLKOR has launched new products such as Hall sensors, ADCs, BMS, sensors, high-speed optocouplers, passive crystal oscillators, high and low-side drivers, half-bridge drivers, isolated gate drivers, RS485 chips, CAN chips, and display power management chips.

image.png

SLKOR power management ICs are designed to directly replace and compete with brands such as Texas Instruments (TI), ON Semiconductor, STMicroelectronics (ST), MPS, Atmel, and AMS. SLKOR’s products are pin-to-pin compatible with these brands, matching their electrical performance and operating scenarios. In some cases, SLKOR’s products even exceed the performance and specifications of their competitors.

image.png

For example, SLKOR’s driver IC SL27511 (SOT-23) is a replacement for Texas Instruments’ UCC27511DBVR, and the SLKOR driver IC SL27517 (SOT-23) is equivalent to TI’s UCC27517DBVR. These driver ICs offer a direct pin-to-pin substitution while maintaining similar or superior performance characteristics.

image.png

SLKOR offers a wide range of power management and driver ICs that are designed as pin-to-pin replacements for products from leading brands, such as ON Semiconductor, Diodes, Texas Instruments (TI), STMicroelectronics, Infineon, and others. Some of the key SLKOR products include:

 

l SL8402 replaces NCV8402 (ON Semiconductor), ZXMS6005DGQ (Diodes), NSE11409-Q1 (Naxin Micro).

l SL27523 replaces UCC27523 (Texas Instruments).

l SL27524 replaces UCC27524 (Texas Instruments).

l SL27525 replaces UCC27525 (Texas Instruments).

l SL4139 (SOT-23-5) is a direct replacement for CAT4139 (ON Semiconductor).

l SL401 (SOT-23-6) is a replacement for BCR401 (Infineon).

l SL3405S replaces BTS3405G (Infineon).

l SL4949 replaces L4949E (STMicroelectronics), TLF4949 (Infineon), NCV4949 (ON Semiconductor).

l SL4275 (TO-252-5) replaces TLE4275 (Infineon), MP2014 (MPS), BD42754 (ROHM), TLE4275-Q1 (TI), TPS7B87-Q1 (TI).

l SL4275-G replaces TLE42754G (Infineon), TLE4275-Q1 (TI), NCV4275C (ON Semiconductor), NCV4290 (ON Semiconductor), NCV8675 (ON Semiconductor), NJW4185 (Nippon Chemi-Con), BD42754 (ROHM).

l SL4264-2 replaces TLE4264 (Infineon), TPS7B69-Q1 (TI), LM2936Q (TI), NCV8664 (ON Semiconductor), NCV4266-2C (ON Semiconductor).

l SL42744D replaces TLE42744 (Infineon), NJW4187 (Nippon Chemi-Con), NJW4185 (Nippon Chemi-Con), NCV7800 (ON Semiconductor), NCV4274 (ON Semiconductor), TL720M05-Q1 (TI).

l SL42764 replaces TLE42764 (Infineon), TPS7B86-Q1 (TI), NCV4276C (ON Semiconductor), NJW4186 (Nippon Chemi-Con).

l SL4284 replaces TLE4284 (Infineon).

l SL2044 replaces U2044.

l SL8366 is a DC-DC power chip that replaces TLE8366.

l SL121S101 replaces ADC121S101.

l SL101S101/ADC101S101, SL081S101 replaces ADC081S101.

l SL121S051 replaces ADC121S051.

l SL101S05, SL081S0511 replaces ADC101S051, ADC081S051 (SOT-23-6).

These products are designed to provide equivalent or superior performance while maintaining compatibility with existing designs from major semiconductor companies.

image.png

After continuous efforts from the engineering team and the information department, SLKOR’s official website (www.slkoric.com) has become a platform for learning and communication within the semiconductor industry. SLKOR Semiconductor adheres to the company ethics of fairness, openness, cooperation, and win-win, growing together with partners in the integrated circuit ecosystem and striving to become a “leading semiconductor enterprise.”

SLKOR’s products include the following key replacements and cross-references to those from leading brands:

l SL121S021 replaces ADC121S021 (Analog Devices, ADI).

l SL101S021 replaces ADC101S021 (Analog Devices, ADI).

l SL081S021 replaces ADC081S021 (Analog Devices, ADI).

l SL7886 replaces ADS7886 (Analog Devices, ADI).

l SL7887, SL7888, SL7866 replace ADS7887, ADS7888, ADS7866 (Analog Devices, ADI).

l SL-FW-TRS-5.5D1 replaces MLS90614BAF/BBF (Mairach).

l SL27531, SL27624MS replace UCC27531DBVR, UCC27624DR (Texas Instruments).

l SL27714 replaces UCC27714 (Texas Instruments).

l SL21814 fully replaces IR21814/IRS21814 (International Rectifier).

l SL2110 replaces IR2110S (International Rectifier).

l SL2003, SL2004 replace IRS2003S, IRS2004 (International Rectifier).

l SL2103 fully replaces IR2103S (International Rectifier).

l SL8205FC replaces SY8205FCC (Sipex).

l SL82C250T replaces PCA82C250T (NXP).

l SL65HVD230DR, SL65HVD232DR, SL65HVD233DR replace SN65HVD230DR, SN65HVD232DR, SN65HVD233DR (Texas Instruments).

l SL65HVD234DR replaces SN65HVD234DR (Texas Instruments).

l SL3232EESE replaces MAX3232E (Maxim Integrated).

l SL65HVD08DR replaces SN65HVD08DR (Texas Instruments).

l SL3088EESA replaces MAX3088E (Maxim Integrated).

l SL3490EESA replaces MAX3490E (Maxim Integrated).

l SL9062C replaces TLV9062 (Texas Instruments).

l SL9062D, SL2122C replace TLV9062 (Texas Instruments) and NJM2122 (Nippon Chemi-Con).

l SL6802 replaces BV6802 (Bofa).

l SL5350SDR, SL5350MDR replace UCC5350 (Texas Instruments).

These products are engineered to deliver equivalent or superior performance and are fully compatible with existing designs, offering solutions in a wide range of applications across the semiconductor industry.

image.png

Mr. Song Shiqiang mentioned that SLKOR’s integrated circuit product series can be paired with Kinghelm’s products from Kinghelm Electronics, including their Beidou GPS dual-mode antennas, IPEX connectors, RF coaxial cables, WiFi, Bluetooth, NB-IoT RF antennas, Zigbee, UWB, GSM antenna series, RFID electronic tags, military-grade RF connectors, automotive-grade SMA, SMB, FAKRA RF connectors, and coaxial cables. These products can be used in electronic information terminal devices.

image.png

Kinghelm’s RF connectors and components, such as the SMA half-threaded panel mount connector (KH-SMA-K513-G) and IPEX antenna connector (KH-IPEX-K501-29), are designed to compete with and replace those from Murata, Hirose, TDK, Amphenol, TE Connectivity, Molex, Luxshare Precision, Foxconn, Yazaki, JAE, Aerospace Electronics, Yonggui Electronics, Delian Precision, Changying Precision, Yihua Electronics, and XWIT Communications, as well as Beidou GPS antennas. Kinghelm and SLKOR’s products are applied in industries such as smartphones, laptops, service robots, power tools, new energy vehicles, 3C digital products, and IoT hardware.

Media Contact
Company Name: Shenzhen SLKOR Micro Semicon Co., Ltd.
Contact Person: Support
Email: Send Email
Phone: +86 13008868302
Address:2010, Block A, Bairuida Building Vanke City Community Bantian Avenue, Longgang District
City: Shenzhen
Country: China
Website: www.slkoric.com

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: SLKOR Semiconductor Launches New Products: RS485 Chips, CAN Chips, and Half-Bridge Drivers

Marginal Zone Lymphoma Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies

DelveInsight’s, “Marginal Zone Lymphoma Pipeline Insight” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Marginal Zone Lymphoma pipeline landscape. It covers the Marginal Zone Lymphoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Marginal Zone Lymphoma therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Stay ahead with the latest insights! Download DelveInsight’s comprehensive Marginal Zone Lymphoma Pipeline Report to explore emerging therapies, key Marginal Zone Lymphoma Companies, and future Marginal Zone Lymphoma treatment landscapes @ Marginal Zone Lymphoma Pipeline Outlook Report

Key Takeaways from the Marginal Zone Lymphoma Pipeline Report

  • In February 2025:- BeiGene:- The purpose of the study is to compare the efficacy of zanubrutinib plus obinutuzumab versus lenalidomide plus rituximab (R^2) in participants with relapsed/refractory (R/R) follicular lymphoma (FL), as measured by progression-free survival as determined by an independent review committee in accordance with the 2014 modification of the International Working Group on non-Hodgkin lymphoma (NHL) Criteria based on n positron emission tomography and computed tomography (PET/CT), and to compare the efficacy of zanubrutinib plus rituximab versus R^2 in participants with R/R marginal zone lymphoma (MZL), as measured by progression free survival (PFS) assessed by IRC in accordance with CT-based Lugano 2014 Criteria.
  • In February 2025:- Regeneron Pharmaceuticals:- This study is researching an experimental drug called odronextamab (referred to as study drug), in combination with lenalidomide. The study is focused on participants who have one of two types of cancer: follicular lymphoma (FL) or marginal zone lymphoma (MZL) that has come back after treatment (called “relapsed”), or did not respond to treatment (called “refractory”). FL and MZL are subtypes of Non-Hodgkin ‘s lymphoma (NHL).
  • In February 2025:- Oncternal Therapeutics Inc.:- This is Phase 1b/2 study to investigate the safety and effectiveness of the investigational drug, cirmtuzumab, when given in combination with ibrutinib in patients with B-cell lymphoid malignancies. Cirmtuzumab is a monoclonal antibody that attaches to a protein (called ROR 1) that is found on hematologic tumor cells. ROR1 has been shown to play a role in cell signaling that cause leukemia and lymphoma cells to grow and survive. ROR1 is rarely found on healthy cells.
  • In February 2025:- Genmab:- The purpose of the dose-escalation part of the trial is to determine the maximum tolerated dose (MTD) and the recommended Phase-2 dose (RP2D), as well as to establish the safety profile of epcoritamab in Japanese patients with relapsed, progressive or refractory B-cell lymphoma and Japanese patients with B-cell lymphomas that have achieved partial response (PR) or complete response (CR).
  • In February 2025:- Janssen Research & Development LLC:- The purpose of this study is to evaluate the efficacy and safety of PCI-32765 (ibrutinib) administered in combination with either bendamustine and rituximab (BR) or rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in adult participants with previously treated indolent Non-Hodgkin lymphoma.
  • DelveInsight’s Marginal Zone Lymphoma pipeline report depicts a robust space with 50+ active players working to develop 50+ pipeline therapies for Marginal Zone Lymphoma treatment.
  • The leading Marginal Zone Lymphoma Companies such as Incyte Corporation, HUTCHMED, InnoCare Pharma, ENTEROME SA, Beijing Mabworks Biotech Co., Ltd., ADC Therapeutics, MEI Pharma, Inc., Genentech, Inc., Novartis, AstraZeneca, Kite Pharma, Roche, Oncternal Therapeutics, Inc., Celgene, IGM Biosciences, Inc., Loxo Oncology, Genmab, ArQule, Sound Biologics, Adicet Bio, Inc., Celldex Therapeutics, TG Therapeutics, Inc., VelosBio Inc., Newave Pharmaceutical Inc., Boryung Pharmaceutical Co., Ltd., Cellectar Biosciences, Inc., Bio-Path Holdings, Inc., Nurix Therapeutics, Inc. and others.
  • Promising Marginal Zone Lymphoma Therapies such as Pirtobrutinib, Obinutuzumab, Loncastuximab tesirine 150 µg/Kg, Copanlisib, Rituximab, Venetoclax, and others.

Discover how the Marginal Zone Lymphoma treatment paradigm is evolving. Access DelveInsight’s in-depth Marginal Zone Lymphoma Pipeline Analysis for a closer look at promising breakthroughs @ Marginal Zone Lymphoma Clinical Trials and Studies

Marginal Zone Lymphoma Emerging Drugs

  • Tafasitamab: Incyte Corporation

Tafasitamab is an investigational humanized Fc-engineered monoclonal antibody directed against CD19. In 2010, MorphoSys licensed exclusive worldwide rights to develop and commercialize tafasitamab from Xencor, Inc. Tafasitamab incorporates an XmAb® engineered Fc domain, which is intended to lead to a significant potentiation of antibody-dependent cell-mediated cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP), thus aiming to improve a key mechanism of tumor cell killing. The therapy is currently in Phase III stage of clinical trial evaluation to treat Marginal Zone Lymphoma.

  • Amdizalisib (HMPL-689): HUTCHMED

The investigational drug candidate amdizalisib is a novel, selective small molecule inhibitor targeting the isoform phosphoinositide 3’-kinase delta (PI3Kδ), a key component in the B-cell receptor signaling pathway. We have designed amdizalisib with increased PI3Kδ isoform selectivity. Amdizalisib’s pharmacokinetic properties have been found to be favorable with good oral absorption, moderate tissue distribution and low clearance in pre-clinical pharmacokinetic studies. Amdizalisib is being investigated in studies in the U.S., Europe, China and Australia in various subtypes of advanced relapsed or refractory non-Hodgkin’s lymphoma, including follicular lymphoma and marginal zone lymphoma.

  • Orelabrutinib: InnoCare Pharma

Orelabrutinib is a small molecule Bruton’s tyrosine kinase inhibitor (BTKi) developed for the treatment of cancer and in development for the potential treatment of autoimmune diseases. In the field of oncology, InnoCare received approval for orelabrutinib from the China National Medical Products Administration (NMPA) in two indications: the treatment of patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL)/small lymphocytic lymphoma (R/R SLL), and the treatment of patients with relapsed/refractory mantle cell lymphoma (R/R MCL). Currently, it is in Phase II stage of clinical trial evaluation to treat Marginal Zone Lymphoma (MZL).

  • EO2463: Enterome

EO2463 is an innovative, off-the-shelf microbiome-peptide based cancer vaccine that combines four microbiome-peptides of B lymphocyte-specific lineage markers. EO2463 is designed to trigger the immune system into recognizing B cells as bacterial (i.e. non-self) and eliciting a targeted cell-killing response. The clinical rationale behind targeting these specific lineage cell markers is to induce the full depletion of malignant B lymphocytes that cause NHL.

The Marginal Zone Lymphoma pipeline report provides insights into

  • The report provides detailed insights about companies that are developing therapies for the treatment of Marginal Zone Lymphoma with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Marginal Zone Lymphoma Treatment.
  • Marginal Zone Lymphoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Marginal Zone Lymphoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Marginal Zone Lymphoma market.

Get a detailed analysis of the latest innovations in the Marginal Zone Lymphoma pipeline. Explore DelveInsight’s expert-driven report today! @ Marginal Zone Lymphoma Unmet Needs

Marginal Zone Lymphoma Companies

Incyte Corporation, HUTCHMED, InnoCare Pharma, ENTEROME SA, Beijing Mabworks Biotech Co., Ltd., ADC Therapeutics, MEI Pharma, Inc., Genentech, Inc., Novartis, AstraZeneca, Kite Pharma, Roche, Oncternal Therapeutics, Inc., Celgene, IGM Biosciences, Inc., Loxo Oncology, Genmab, ArQule, Sound Biologics, Adicet Bio, Inc., Celldex Therapeutics, TG Therapeutics, Inc., VelosBio Inc., Newave Pharmaceutical Inc., Boryung Pharmaceutical Co., Ltd., Cellectar Biosciences, Inc., Bio-Path Holdings, Inc., Nurix Therapeutics, Inc. and others.

Marginal Zone Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

  • Inhalation
  • Inhalation/Intravenous/Oral
  • Intranasal
  • Intravenous
  • Intravenous/ Subcutaneous
  • NA
  • Oral
  • Oral/intranasal/subcutaneous
  • Parenteral
  • Subcutaneous

Marginal Zone Lymphoma Products have been categorized under various Molecule types such as

  • Antibody
  • Antisense oligonucleotides
  • Immunotherapy
  • Monoclonal antibody
  • Peptides
  • Protein
  • Recombinant protein
  • Small molecule
  • Stem Cell
  • Vaccine

Download DelveInsight’s latest report to gain strategic insights into upcoming Marginal Zone Lymphoma Therapies and key Marginal Zone Lymphoma Developments @ Marginal Zone Lymphoma Market Drivers and Barriers, and Future Perspectives

Scope of the Marginal Zone Lymphoma Pipeline Report

  • Coverage- Global
  • Marginal Zone Lymphoma Companies-Incyte Corporation, HUTCHMED, InnoCare Pharma, ENTEROME SA, Beijing Mabworks Biotech Co., Ltd., ADC Therapeutics, MEI Pharma, Inc., Genentech, Inc., Novartis, AstraZeneca, Kite Pharma, Roche, Oncternal Therapeutics, Inc., Celgene, IGM Biosciences, Inc., Loxo Oncology, Genmab, ArQule, Sound Biologics, Adicet Bio, Inc., Celldex Therapeutics, TG Therapeutics, Inc., VelosBio Inc., Newave Pharmaceutical Inc., Boryung Pharmaceutical Co., Ltd., Cellectar Biosciences, Inc., Bio-Path Holdings, Inc., Nurix Therapeutics, Inc. and others.
  • Marginal Zone Lymphoma Therapies- Pirtobrutinib, Obinutuzumab, Loncastuximab tesirine 150 µg/Kg, Copanlisib, Rituximab, Venetoclax, and others.
  • Marginal Zone Lymphoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Marginal Zone Lymphoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Which companies are leading the race in Marginal Zone Lymphoma drug development? Find out in DelveInsight’s exclusive Marginal Zone Lymphoma Pipeline Report—access it now! @ Marginal Zone Lymphoma Emerging Drugs and Major Companies

Table of Content

  1. Introduction
  2. Executive Summary
  3. Marginal Zone Lymphoma: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Marginal Zone Lymphoma – DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Tafasitamab: Incyte Corporation
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. Orelabrutinib: InnoCare Pharma
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I/II)
  14. EO2463: Enterome
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Drug name: Company name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Marginal Zone Lymphoma Key Companies
  21. Marginal Zone Lymphoma Key Products
  22. Marginal Zone Lymphoma- Unmet Needs
  23. Marginal Zone Lymphoma- Market Drivers and Barriers
  24. Marginal Zone Lymphoma- Future Perspectives and Conclusion
  25. Marginal Zone Lymphoma Analyst Views
  26. Marginal Zone Lymphoma Key Companies
  27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/knee-reconstruction-devices-market

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Marginal Zone Lymphoma Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies

Talent Acquisition And Staffing Technology Market Expected to Reach USD 67.32 Billion with a 9.93% CAGR by 2034

“Talent Acquisition and Staffing Technology empowers organizations to find, engage, and hire top talent faster through innovation, automation, and data-driven insights”
Talent Acquisition and Staffing Technology streamlines recruitment processes through AI-driven automation, data analytics, and digital platforms to enhance hiring efficiency and candidate experience.

Talent Acquisition and Staffing Technology Market Overview

According to a new report published by Market Research Future (MRFR), Talent Acquisition and Staffing Technology Market is expected to expand from USD 28.71 billion in 2025 to USD 67.32 billion by 2034, reflecting a compound annual growth rate (CAGR) of 9.93% during the forecast period (2025–2034). Furthermore, the market was valued at USD 26.11 billion in 2024.

The Talent Acquisition and Staffing Technology Market is experiencing rapid growth as businesses worldwide seek advanced solutions to streamline their hiring processes and improve workforce management. With the increasing adoption of artificial intelligence (AI), machine learning (ML), and automation, organizations are leveraging innovative tools to enhance candidate sourcing, screening, interviewing, and onboarding. The demand for data-driven recruitment strategies, remote hiring solutions, and diversity and inclusion initiatives further fuels the expansion of this market. Additionally, the rise of the gig economy and freelance workforce has led to the need for adaptable and scalable hiring technologies that cater to both permanent and contingent staffing requirements.

Download Sample Report (Get Full Insights in PDF – 128 Pages) at: https://www.marketresearchfuture.com/sample_request/26520

Key Companies in the Talent Acquisition And Staffing Technology Market Include:

  • Avionté
  • Oracle
  • Greenhouse
  • Lumesse
  • Kronos Incorporated
  • iCIMS
  • Ceridian HCM
  • SAP
  • ADP
  • Bullhorn
  • iCIMS
  • IBM
  • Workday
  • PeopleFluent
  • LinkedIn

These organizations offer a range of AI-powered recruitment platforms, applicant tracking systems (ATS), and human resource management solutions that help businesses optimize their hiring processes. Emerging startups and niche players like iCIMS, SmartRecruiters, Jobvite, and HireVue are also gaining traction by providing specialized recruitment automation tools, AI-driven assessments, and video interviewing solutions. Additionally, major job boards and recruitment marketplaces like Indeed and Glassdoor continue to play a significant role in shaping the industry by offering innovative job-matching algorithms and employer branding solutions.

The Talent Acquisition and Staffing Technology Market can be segmented based on technology, application, organization size, industry vertical, and deployment mode. By technology, key segments include AI-powered recruitment tools, cloud-based applicant tracking systems, predictive analytics, and video interviewing platforms. In terms of application, the market is categorized into candidate sourcing, screening and assessment, interview management, onboarding, and workforce analytics. Organization size segmentation covers small and medium-sized enterprises (SMEs) and large enterprises, with different adoption levels based on budget constraints and hiring volumes. Industry verticals such as IT and telecom, healthcare, retail, BFSI, manufacturing, and education are key consumers of recruitment technology solutions. Deployment modes include on-premise and cloud-based solutions, with cloud adoption witnessing significant growth due to its scalability and cost-efficiency.

Buy Now Premium Research Report – https://www.marketresearchfuture.com/checkout?currency=one_user-USD&report_id=26520

Market dynamics are driven by several factors, including the increasing reliance on data-driven recruitment, the growing need for automation, and the shift towards remote hiring and virtual onboarding. Companies are prioritizing candidate experience and employer branding, leading to the development of personalized recruitment marketing strategies. The integration of AI and ML into recruitment processes enables recruiters to identify top talent more efficiently while reducing biases in hiring. However, challenges such as data privacy concerns, high implementation costs, and resistance to technological adoption among traditional HR teams can hinder market growth. Additionally, regulatory compliance related to hiring practices and labor laws poses complexities for multinational organizations investing in staffing technology solutions.

Recent developments in the Talent Acquisition and Staffing Technology Market highlight the ongoing evolution of recruitment technologies. AI-driven chatbots and virtual assistants are becoming mainstream, assisting recruiters in engaging with candidates and answering their queries in real time. Predictive analytics is gaining traction, allowing organizations to assess candidate potential based on historical hiring data and performance metrics. The rise of skills-based hiring has led to the development of assessment tools that evaluate candidates based on competencies rather than traditional resumes. Moreover, blockchain technology is being explored for secure and verifiable credential verification, reducing the risk of fraudulent qualifications. Companies are also focusing on enhancing diversity, equity, and inclusion (DEI) through bias-free AI recruitment solutions that ensure fair candidate selection processes.

Browse In-depth Market Research Report – https://www.marketresearchfuture.com/reports/talent-acquisition-staffing-technology-market-26520

Regionally, North America leads the Talent Acquisition and Staffing Technology Market due to the strong presence of technology providers and the early adoption of AI-powered hiring solutions. The United States, in particular, is at the forefront, with large enterprises investing heavily in recruitment automation to attract top talent in competitive industries like IT, finance, and healthcare. Europe follows closely, with countries such as the UK, Germany, and France emphasizing compliance-driven hiring solutions and diversity-focused recruitment strategies. The Asia-Pacific region is witnessing rapid growth, driven by digital transformation initiatives in emerging economies like India, China, and Japan. The increasing penetration of cloud-based HR solutions and mobile-first recruitment platforms further fuels market expansion in this region. Latin America and the Middle East & Africa are gradually adopting staffing technology, with a focus on improving workforce mobility and addressing skill gaps through digital hiring solutions.

In conclusion, the Talent Acquisition and Staffing Technology Market is poised for continuous growth, driven by advancements in AI, automation, and data analytics. As businesses increasingly prioritize efficiency, diversity, and candidate experience in recruitment, the demand for innovative hiring solutions is expected to surge. While challenges such as regulatory compliance and data privacy persist, ongoing technological innovations and strategic collaborations among market players will shape the future of recruitment technology. Organizations that embrace digital hiring trends and invest in next-generation staffing solutions will gain a competitive edge in attracting and retaining top talent in the evolving job market.

Explore MRFR’s Related Ongoing Coverage In ICT Domain:

B2B SaaS Market – https://www.marketresearchfuture.com/reports/b2b-saas-market-42826

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.

Media Contact
Company Name: Market Research Future
Contact Person: Media Relations
Email: Send Email
Country: United States
Website: https://www.marketresearchfuture.com

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Talent Acquisition And Staffing Technology Market Expected to Reach USD 67.32 Billion with a 9.93% CAGR by 2034

The Latest Football Kits in Spain: A Look at 2024 Designs

“The 2024 football kits are displayed vividly. FC Barcelona’s deep blue and garnet stripes and Real Madrid’s elegant white with gold accents are featured prominently. Atlético Madrid’s bold red and white stripes and Sevilla FC’s classic red with black trim are shown behind. Spain’s national team jerseys, with the home kit in red and the away kit in icy blue, are visible to the side. The background includes a football pitch, highlighting the kits’ connection to the game.”
Football kits are more than just uniforms; they are a canvas of tradition, innovation, and identity. Each design tells a story of its club or nation, blending past and future into a fabric that players wear with pride and fans cherish.

As the 2024 football season kicks off, Spanish football fans are treated to a fresh array of club and national team kits that reflect both traditional elements and modern design trends. From La Liga’s elite teams to Spain’s national squad, the latest football jerseys are making waves with their innovative styles and technological advancements.

FC Barcelona: Embracing Tradition with a Modern Twist

FC Barcelona’s new kit stays true to its iconic stripes while incorporating subtle updates. The 2024 home jersey features the classic blaugrana stripes but with a more streamlined and gradient effect, blending deep blue and garnet shades.visit www.camisetasfutboleses.com. The collar has been redesigned for a sleek, contemporary look, and the breathable fabric ensures maximum comfort for players. The away kit presents a bold departure with a vibrant color scheme inspired by Catalan culture, making a strong visual impact on and off the pitch.

Real Madrid: Elegance Meets Innovation

Real Madrid’s latest home jersey continues their tradition of sophistication with a pristine white base adorned by gold accents. visit camisetas futbol Bratas. The new design introduces a subtle texture that catches the light, adding a refined touch to the classic look. The away kit showcases a dynamic purple hue with geometric patterns that highlight the club’s forward-thinking approach. The use of cutting-edge fabric technology ensures durability and flexibility, enhancing player performance throughout the season.

Atlético Madrid: Bold and Distinctive

Atlético Madrid’s 2024 kits embrace boldness with a striking combination of red and white vertical stripes for the home jersey. visit camisetas futbol es. This season’s design adds a modern flair with a slightly curved stripe pattern, providing a unique visual appeal. The away jersey features a deep navy blue with subtle red accents, reflecting the club’s strong and resilient spirit. Both kits are designed with advanced moisture-wicking technology to keep players cool under pressure.

Sevilla FC: Classic with a Contemporary Edge

Sevilla FC’s new home jersey pays homage to their classic red color, enhanced with sleek black trim. The design incorporates a minimalist approach with a focus on clean lines and a sophisticated look. The away kit diverges with a stylish black base, complemented by silver detailing that adds a touch of elegance. The jerseys are crafted from lightweight materials, offering players a balance of comfort and performance.

Spain National Team: National Pride and Innovation

The Spanish national team’s new kits for 2024 reflect a blend of tradition and modernity. The home jersey features a vibrant red color with subtle yellow and blue accents that nod to Spain’s national flag. The away kit introduces a fresh, icy blue hue with intricate patterns inspired by Spanish art and architecture. Both kits utilize advanced fabric technology to provide optimal comfort and flexibility, supporting the team as they compete on the international stage.

For more details and to explore these exciting new designs, visit camisetasfutboleses.com, where you can find the latest football jerseys and stay updated on the newest trends in football fashion.

Conclusion

The 2024 football season in Spain brings a dynamic range of kit designs that celebrate both heritage and innovation. Whether you’re a supporter of Barcelona, Real Madrid, Atlético Madrid, Sevilla, or the Spanish national team, the latest jerseys are sure to excite fans and enhance the football experience. With a focus on both style and performance, these new kits are set to make a significant impact on the pitch and in the stands.

Media Contact
Company Name: Camisetasfutboleses.com
Contact Person: Media Relations
Email: Send Email
Phone: +8616659306369
Address:Calle del Rio
City: Salamanca
Country: Spain
Website: https://www.camisetasfutboleses.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: The Latest Football Kits in Spain: A Look at 2024 Designs

KingSpec Wins Newegg’s Eggie Award: 2025 Partner of the Year – Recognizing Innovation and Quality in Storage Solutions

KingSpec Electronics Technology Co., Ltd., a recognized provider of reliable and high-performance storage solutions, has been awarded the prestigious 2025 EGGIE AWARD – Partner of the Year by Newegg, one of the world’s largest online retailers. Newegg is a leading global e-commerce platform focused on computer hardware, electronics, and tech products. It is a trusted destination for tech enthusiasts, offering top-tier products and outstanding customer service on a global scale. This recognition underscores KingSpec’s commitment to product excellence, continuous innovation, and strategic partnerships across the storage industry.

A Leader in SSD Technology

Founded in 2007, KingSpec has become an influential player in the SSD market. As a “National High-tech Enterprise” recognized by the Chinese government, KingSpec is known for delivering dependable and cutting-edge one-stop storage solutions. The company has built strong industry partnerships, providing innovative storage solutions for various applications, including consumer electronics, enterprise data centers, gaming, and beyond.

Global Recognition for Excellence

KingSpec has always prioritized product quality, earning international certifications including CE, FCC, RoHS, REACH, and KC. In addition, the company is a member of the SSD Association (ASSD), ensuring access to the latest technology and industry standards. KingSpec’s manufacturing facility is equipped with advanced automated SMT production lines and adheres to ISO 9001 standards, maintaining rigorous quality control throughout production.

Award-Winning Products

KingSpec’s commitment to innovation is evident in its range of high-performance SSDs, including:

  • M.2 NVMe PCIe 4.0 SSD – XG7000: Ideal for PS5 storage upgrades, the XG7000 offers up to 4TB of storage capacity, speeds up to 7400MB/s, and advanced heat dissipation technology, making it the ultimate choice for gamers.

  • 2.5 inch SATA SSD – P3: With capacities up to 4TB, this series provides outstanding performance and durability, providing a significant speed boost, it is the ideal choice for users seeking faster data access and enhanced storage performance.

  • DDR4 RGB Memory – Silver X: This memory module offers a high-performance, visually striking upgrade, supporting speeds up to 3600MT/s and featuring customizable RGB lighting for an enhanced gaming experience.

  • DDR5 RGB Memory – Templar: With speeds reaching up to 7600MT/s, Templar ensures rapid and efficient data transfer, enhancing system responsiveness. Featuring a 16GB capacity, it’s perfect for gaming and demanding applications. The sleek, RGB-lit design adds a touch of style to your setup, combining performance with visual appeal.

  • USB SSD – US5: Designed for iPhone, the US5 supports USB 3.2 Gen 2×2 speeds up to 20Gbps, offering fast and reliable storage expansion with up to 2TB of capacity.

Innovation and Cutting-Edge Technology

KingSpec’s products leverage advanced technologies to deliver exceptional performance and reliability. Some of its products incorporate 3D NAND flash for enhanced speed and feature intelligent management systems such as TRIM, S.M.A.R.T., and Wear Leveling, ensuring optimized performance and longevity. Additionally, KingSpec’s SSDs integrate LDPC ECC (Low-Density Parity Check Error Correction) and PLP (Power Loss Protection) technologies, offering superior data integrity and security.

A Global Network of Partners

Thanks to its ongoing commitment to quality and innovation, KingSpec has built a strong global presence. The company’s products are trusted by partners in Europe, America, Asia, and beyond. With its products available across key international markets, KingSpec continues to grow its global network of satisfied customers.

Looking Ahead

Looking forward, KingSpec will continue to invest in research and development to push the boundaries of SSD performance. With a strong emphasis on quality, reliability, and innovation, the company aims to provide industry-leading storage solutions that meet the evolving needs of consumers and businesses alike. KingSpec remains committed to expanding its global presence and solidifying its position as a top-tier provider of storage technology.

About KingSpec

KingSpec Electronics Technology Co., Ltd. is a leading provider of high-performance one-stop storage solutions, including SSDs, DRAM, and other memory products. KingSpec provides tailored storage solutions for consumer-grade, industrial-grade, and enterprise-grade applications, ensuring that each product delivers optimal performance, reliability, and security to meet the specific demands of different sectors. With a strong commitment to research, development, and manufacturing, KingSpec offers cutting-edge products that meet the needs of diverse industries worldwide.

For more information, visit www.kingspec.com

Media Contact
Company Name: Shenzhen Kingspec Electronics Technology Co.Ltd
Contact Person: Morffin
Email: Send Email
Phone: +8675526985379
City: Shenzhen
Country: China
Website: www.kingspec.com

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: KingSpec Wins Newegg’s Eggie Award: 2025 Partner of the Year – Recognizing Innovation and Quality in Storage Solutions

Flat Out Digger Hire is revolutionizing the Australian market by providing with a safer, more reliable, and hassle-free excavation

“Flat Out Digger + Equipment Hire”

Gold Coast Excavation Hire: Safe, Reliable & Job-Ready Equipment with Flat Out Digger Hire

When it comes to Gold Coast excavation hire, having the right equipment makes all the difference. That’s why Flat Out Digger Hire is setting the standard for safe, reliable, and high-performance excavation equipment in Burleigh Heads and beyond.

Unlike other companies still using outdated excavators and trailers, we invest in modern, top-tier machinery that meets the highest safety and performance standards. Our job-ready excavators, diggers, and trailers are built for efficiency — and the best part? No license is required to operate them!

Why Flat Out Digger Hire is the #1 Choice for Gold Coast Excavation Hire

• Premium Equipment – No Outdated Machines – We don’t cut corners on quality. Every excavator, digger, and trailer in our fleet is modern, well-maintained, and fully job-ready, so you can work with confidence.

• No License Required – Hassle-Free Operation – Our easy-to-use excavation equipment is designed for both professionals and DIYers—no license needed. Whether you’re a contractor or a first-time user, we make excavation hire simple and accessible.

• Fast & Reliable Delivery – Equipment When You Need It – Need a digger on-site ASAP? We offer quick and efficient delivery across Burleigh Heads and the entire Gold Coast, ensuring you get the right equipment when and where you need it.

• Safety First – Fully Compliant with All Paperwork – Every hire includes all necessary safety paperwork, so you can start your project with total peace of mind, knowing you’re covered. Safety is our top priority!

• Quality Guarantee – Backed by Our Commitment to Excellence – We take pride in offering high-performance excavation equipment backed by our Flat Out Digger Hire Quality Guarantee. If it’s not up to standard, we’ll make it right—no questions asked.

Gold Coast & Burleigh Heads Excavation Hire – Ready When You Are!

Located in Burleigh Heads, QLD, Flat Out Digger Hire proudly serves Gold Coast, Tweed Heads, and surrounding areas, delivering top-notch excavation hire services for both residential and commercial projects. Whether you’re working on a backyard renovation, landscaping project, or large-scale excavation, we’ve got the right excavators, diggers, and trailers to get the job done.

Need a Digger? Hire from the Best in Gold Coast Excavation Hire!

For fast, safe, and reliable excavation equipment hire, trust Flat Out Digger Hire. With quick delivery, no license required, and the highest safety standards, we’re making excavation hire in the Gold Coast easier than ever.

Media Contact
Company Name: Flatout Digger Hire
Contact Person: Jesse
Email: Send Email
Phone: 0432398662
Address:Unit 4, 15/17 Ramly Drive, Burleigh Heads
City: Gold Coast
State: 4220 QLD
Country: Australia
Website: https://www.flatoutdiggerhire.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Flat Out Digger Hire is revolutionizing the Australian market by providing with a safer, more reliable, and hassle-free excavation